Physician profile
Anthony Ea
NPI 1700203221
$31,285.07
in general payments reported to CMS, 2019-2025
30 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $4,481 · 2021: $512 · 2022: $476 · 2023: $1,182 · 2024: $1,083 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $5,211 · Travel and Lodging: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,812.50 |
| Food and Beverage | $5,211.15 |
| Travel and Lodging | $776.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21,962.03 | 2019-2025 | Amplatzer, Cardiomems, Amplatzer Talisman |
| Medtronic Vascular, INC. | $3,002.60 | 2019-2020 | |
| Boston Scientific Corporation | $1,896.25 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Philips North America LLC | $1,135.24 | 2023-2025 | Coronary Other, (5044) Mcot, Igt Devices Undivided |
| Medtronic, INC. | $593.33 | 2021-2025 | Onyx Frontier, Aurora Ev-Icd Mri Surescan, Omniasecure Mri Surescan |
| Novartis Pharmaceuticals Corporation | $300.18 | 2022-2025 | |
| Heartflow, INC. | $273.45 | 2023-2024 | Ffrct |
| Shockwave Medical, INC | $261.10 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.90 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $182.41 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $182.16 | 2021-2022 | |
| Amgen INC. | $162.56 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $159.94 | 2022-2025 | |
| Biosense Webster, INC. | $146.86 | 2025 | Carto 3 |
| Edwards Lifesciences Corporation | $130.00 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $120.11 | 2020 | |
| Alnylam Pharmaceuticals INC. | $108.45 | 2022-2025 | Amvuttra |
| Angiodynamics, INC. | $84.56 | 2023 | Bioflo |
| E.R. Squibb & Sons, L.L.C. | $80.83 | 2021-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $80.37 | 2022-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $43.46 | 2023-2024 | Verquvo |
| Cordis US Corp. | $39.09 | 2025 | Mynx Control Venous |
| Sanofi-Aventis U.S. LLC | $30.21 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $22.76 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $22.43 | 2022 | |
| Amarin Pharma, INC. | $20.04 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.14 | 2023 | Arcalyst |
| Octapharma USA, INC. | $17.03 | 2025 | Fibryga |
| Cleerly, INC. | $16.43 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Cardiovascular Systems INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.